Caixa Empreender Award | Extremo Chem (Cotec)

2 7 T H J A N U A R Y 2 0 1 5

Team

• Founders:- Rita Ventura - Eva Lourenço- Christopher Maycock- Based on 15 years of academic research

• Business development team:- Pedro Vilarinho, COTEC Portugal- Filipe Aguiar, 73100 – Infraventus

- Founded on November 2013

- Investor: Setenta e Três Mil e Cem, Lda.

ExtremoChem is a start-up company aiming at the development and commercialisation of chemically synthesised novel excipients for the stabilisation of biologics.

Problem/Opportunity

Problem/Opportunity

Active Protein Inactive Protein

Heat and cold

Current solution: cold chain

Certified container

Manufacturers Patient

Distributors

Current solution issues:

temperature excursions

Degradation - loss of efficacy and safety

“Improved thermostability of vaccines is an area of interest for

us”

Senior Director External Scientific Affairs,Merck & Co., USA

Market need

Our solution

Archaeoglobus fulgidus

Hydrothermal vents

• Chemically synthesised analogues of protein stabilising natural compounds with improved stabilisation properties

Our solution

STABILISATION OF BIOPHARMACEUTICALS

Heat and cold

Active Protein Active Protein

Chemical Compound

Value Proposition

Synthesis of new compounds for stabilisation of biopharmaceuticals over a wider range of

temperatures

PHARMACEUTICAL INDUSTRY

Biopharmaceuticals efficacy and safety guaranteed all over the world

• The costs of cold chain failure are estimated to be €5b

• Spin-off of the Imperial College London, 2007

• Excipient mixture derived from seeds and customised to each vaccine - under testing

• Private company based in Cambridge, Massachusetts, founded in 2001

• Liposome encapsulation of vaccine - under clinical trials

Competition

Development status

• Stabilisation of commercially available biopharmaceuticals in the presence of ExtremoChem compounds:

Caninsulin – Porcine insulin, for veterinary use Lantus, Humulin Regular, Actrapid, Insuman Rapid, Insuman

Basal, Humulin NpH, Insulatard - Human Insulin Cervarix and Gardasil – Human papiloma virus vaccine Erythropoietin – Human, recombinant, CHO cells Norditropin SimpleXx – Somatropine, human growth hormone

Development status

• Stabilisation of biopharmaceuticals at room temperature for 10, 15 and 30 days in the presence of ExtremoChem compounds

• Degradation of the proteins at room temperature without added compounds

• The biological activity of the proteins in the presence of our compounds remained the same

IP Protection

• US Provisional Patent submitted during 2013: Hexose derivatives, preparation and uses thereof

• IP Legal advisers: Cooper & Dunham LLP – New York

• PCT application under preparation

• New IP under preparation

Business model

• Co-development for each different indication with relevant pharmaceutical companies

Optimised formulation for the stabilisationof the Active Principle Ingredients (API’s)

• Revenue generated through licensing

Roadmap

2014 2015 2016 2017 2018 2019 ...

IP

Services/Colaborations

Insulins

R&D

2002…

Vaccines

Monoclonal antibodies & Epoetins

EMA

Toxicity Tests

FDA & IPEC

Summary

• ExtremoChem is a tech based start-up

• Commercialisation of new excipients – distribution of biopharmaceuticals without the need of cold chain

• Active and safe biopharmaceuticals all over the world

• Addresses a recognised unmet market need

Thank you for your attention!

Eva Lourenço, [email protected] Ventura, [email protected]

Christopher Maycock, [email protected] Vilarinho, [email protected]

Filipe Aguiar, [email protected]